Cancer Advisor

Pancreatic ductal adenocarcinoma (PDAC) remains among the most treatment-resistant solid tumors. Despite decades of molecular characterization and incremental therapeutic advances, durable responses are rare, and recurrence is nearly universal. Across this landscape, a clear pattern emerges: combination therapies repeatedly outperform single-agent strategies in preclinical studies. Whether framed as targeted drug pairings, multi-agent regimens, or systems-level interventions, contemporary research consistently emphasizes that PDAC cannot be effectively controlled through single-mechanism interventions. This article examines the biological rationale for this convergence, with particular attention to cancer stem cells (CSCs) as a central driver of resistance and relapse. Pancreatic Cancer as an Adaptive System Traditional drug development assumes that disabling a dominant driver is sufficient to halt tumor progression. In PDAC, this assumption is challenged by several features: Extensiv...

Executive Summary In recent years, two seemingly distant worlds of cancer research have begun to converge in unexpected ways. On one side, mainstream oncology is increasingly focused on multi-drug combination strategies designed to block oncogenic drivers and preempt resistance. On the other, interest has grown around repurposed drug combinations — such as ivermectin, fenbendazole, and mebendazole — proposed to exert anticancer effects through metabolic and cellular stress pathways. While these approaches differ profoundly in evidentiary strength, regulatory status, and clinical readiness, they share a common conceptual foundation: cancer is an adaptive system that rarely yields to single-target intervention . Understanding where these strategies align — and where they fundamentally diverge — is essential for separating scientific insight from speculation. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created with Biorender.com. Source:  Nat...